Navigation Links
Treatment corrects severe insulin imbalance in animal studies
Date:7/31/2008

osing such lesions and performing the curative surgery on newborns.

However, when abnormal cells are distributed throughout the pancreas in so-called diffuse HI, surgeons must remove nearly all the pancreas. This relieves HI in about a quarter of cases, but leaves the majority of patients at high risk for insulin imbalance, in which blood glucose levels are too low (hypoglycemia) or too high, resulting in diabetes.

The new study makes use of a peptide (an amino acid compound) called exendin-(9-39) that blocks the action of a specific hormone receptor in beta cells. Building on their previous work using exendin-(9-39) on normal mice, De Len's study team studied the peptide's effect on a strain of mice that had been genetically engineered to mimic the defect found in children with congenital HI.

When researchers withhold food from those mice, their blood glucose levels become low, a condition called fasting hypoglycemia. Mice who had received exendin-(9-39), however, had significantly higher levels of fasting blood glucose compared to mice that were not treated with the peptide, and reached levels comparable to those in normal, healthy animals. Further studies identified the mechanisms in the hormone signaling system that malfunctions in HI.

The next step, says De Len, is a pilot study now under way to test the effect of exendin-(9-39) in children and adults with congenital HI. If results from the pilot study are promising, her study team expects to progress to a larger clinical trial. "If this peptide can be developed into a treatment for children with this common form of HI, we may have a new tool for controlling their insulin levels and managing their disease," added De Len.

The Congenital Hyperinsulinism Center at Children's Hospital has worldwide prominence in diagnosing and treating this genetic disease. Much of its work builds on pioneering research by Charles A. Stanley, M.D., in identifying the specific gene defec
'/>"/>

Contact: John Ascenzi
Ascenzi@email.chop.edu
267-426-6050
Children's Hospital of Philadelphia
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Video released of rapid Alzheimers improvement after new immune-based treatment
2. Fertility treatment in developing countries; a cycle of IVF for less than $200
3. New treatment approach promising for lymphoma patients in the developing world
4. Treatment delays result in poor outcomes for men with breast cancer
5. Counting tumor cells in blood predicts treatment benefit in prostate cancer
6. Stroke study reveals key target for improving treatment and suggests that Gleevec may help
7. Hypertension treatment effective in reversing vascular damage
8. Rong Li Lab identifies new role of inflammatory protein in PKD and a possible treatment
9. Source of drug-tolerant tuberculosis possibly behind TB relapses, intensity of treatment
10. Novel therapeutic strategy for colon cancer treatment
11. New ballast treatment could protect Great Lakes fish
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/13/2015)... , Feb. 13, 2015 ACT Genomics ... that aims to transform cancer genomic information into ... the company has raised US$ 8 million in the ... in Taipei, Taiwan , ACT ... ACTOnco™. With the aim to implement next generation ...
(Date:2/11/2015)... , February 11, 2015 ... report "Access Control Market by Product (Cards and Readers, ... Military and Defense, Government, Industrial, Healthcare, Education) and By ... by MarketsandMarkets, the Access Control Market is ... growing at a CAGR of 10.6% between ...
(Date:2/5/2015)... North Carolina , 5. Februar 2015 ... Jahr als spezialisiertes Logistikunternehmen und hat eine ... einzige klinische Logistikfirma (Clinical Logistics Organization – ... der neuen Kampagne lautet First , ... Foto: http://photos.prnewswire.com/prnh/20150205/173753 ...
Breaking Biology News(10 mins):ACT Genomics Raises $8 Million in its First Private Funding Round 2Access Control Market Worth $10.4 Billion by 2020 2Access Control Market Worth $10.4 Billion by 2020 3Access Control Market Worth $10.4 Billion by 2020 4Marken startet Kampagne mit Patienten im Mittelpunkt 2Marken startet Kampagne mit Patienten im Mittelpunkt 3
... Princeton engineers have developed a sensor that may revolutionize how ... the process also help ensure the survival of two species ... credit goes to an African frog. In the wild, ... of amino acids -- on its skin to protect it ...
... of Medicine have found that new disease pathways involving ... Gaucher disease, a rare genetic disorder in which fatty ... enlargement, osteoporosis, bone pain, and increased risk of cancer ... lead to less expensive and more effective ways to ...
... COLUMBIA, Mo. If finding the cure for a fungus ... of a detective show, University of Missouri Chemistry Professor John ... high-tech equipment to make a model that could eventually solve ... of Arts and Science, has joined forces with Pablo Sobrado, ...
Cached Biology News:New sensor derived from frogs may help fight bacteria and save wildlife 2New sensor derived from frogs may help fight bacteria and save wildlife 3Cheaper, more effective treatment of type 1 Gaucher disease possible 2X-ray diffraction may play key role in stopping 'kissing bug,' fungus 2
(Date:2/27/2015)... 27, 2015 Bionomics Limited (ASX:BNO, ADR:BMICY) is ... of BNC105 in patients with metastatic renal cancer at ... Florida . The data will be presented by ... Hope Comprehensive Cancer Center in California ... new data identifies Ferritin and IL-8 as two baseline ...
(Date:2/27/2015)... 27, 2015   PureTech , a science and ... disruptive products and technologies in the healthcare sector, announced ... CEO and Member of the Board of Directors of ... "It,s has been a pleasure to know Chris for ... will be working together more closely now," said Dr. ...
(Date:2/26/2015)... 2015   Synageva BioPharma Corp. (NASDAQ: ... therapeutic products for rare disorders, today reported 2014 ... other key objectives, and financial guidance.  Synageva,s management ... 4:30 p.m. EST to review the financial results ... in today,s call by telephone, please dial (877) ...
(Date:2/26/2015)... On behalf of biotech client GenScript USA, ... & Spitzer, P.A. (Wilentz) secured a significant jury ... in excess of $10 million. The jury determined that ... that it improperly hired one or more of GenScript’s ... for judgment notwithstanding the verdict, a new trial, and ...
Breaking Biology Technology:New BNC105 Biomarker Data to be Presented at US Cancer Conference 2New BNC105 Biomarker Data to be Presented at US Cancer Conference 3New BNC105 Biomarker Data to be Presented at US Cancer Conference 4New BNC105 Biomarker Data to be Presented at US Cancer Conference 5Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 2Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 3Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 4Synageva BioPharma Reports 2014 Full Year Financial Results 2Synageva BioPharma Reports 2014 Full Year Financial Results 3Synageva BioPharma Reports 2014 Full Year Financial Results 4Synageva BioPharma Reports 2014 Full Year Financial Results 5Synageva BioPharma Reports 2014 Full Year Financial Results 6Synageva BioPharma Reports 2014 Full Year Financial Results 7Synageva BioPharma Reports 2014 Full Year Financial Results 8Synageva BioPharma Reports 2014 Full Year Financial Results 9Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 2Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 3
... Mich., Oct. 11 Compendia Bioscience, Inc.,today announced ... Track Award from,the National Cancer Institute to support ... Platform for Biopharmaceutical Research and,Development". (Logo: ... Ph.D., who will serve as the principal,investigator for ...
... the prevention and treatment of ... safety and comfort, BATESVILLE, Ind., Oct. 11 ... Hill-Rom subsidiary has,introduced a revolutionary new hospital bed surface ... Hill-Rom(R) E700 Wound Surface (a,low air loss therapy surface) ...
... provides pharmacy staff with the ability to ... manage every pharmaceutical in the hospital, MOUNTAIN VIEW, Calif. ... ), a leading provider,of system solutions to acute healthcare facilities, ... Chambersburg,Hospital has reduced cart-fill time from 16 man-hours to 90 ...
Cached Biology Technology:Compendia Bioscience Announces the Receipt of a $2.4M SBIR Award and Related Management Changes 2Hill-Rom Introduces New Wound Therapy Surface With Innovative Safety and Treatment Features 2Hill-Rom Introduces New Wound Therapy Surface With Innovative Safety and Treatment Features 3Hill-Rom Introduces New Wound Therapy Surface With Innovative Safety and Treatment Features 4Hill-Rom Introduces New Wound Therapy Surface With Innovative Safety and Treatment Features 5Chambersburg Hospital Streamlines Pharmacy Process and Increases Patient Safety With Omnicell WorkflowRx 5.0 2Chambersburg Hospital Streamlines Pharmacy Process and Increases Patient Safety With Omnicell WorkflowRx 5.0 3
A univariate (peak height or area) quantitative multi-component analysis package....
... H-Ala-Cys-Asp-Thr-Ala-Thr-Cys-Val-Thr-His-Arg-Leu-Ala-Gly-Leu-Leu-Ser-Arg-Ser-Gly-Gly-Val-Val-Lys-Asn-Asn-Phe-Val-Pro-Thr-Asn-Val-Gly-Ser-Lys-Ala-Phe-NH 2 (Disulfide ... peptide and 1 ... I-labelled peptide, please see ... ([ 1 2 ...
... is a dramatic breakthrough in accurate, small-volume bulk ... resolution, the micro 1 has unique advantages not ... micro 1 never needs re-calibration as do other ... on an LCD Display , Graphical Row Selection ...
... high-throuput screening of a biological systems phenotype, ... changes in the expression levels of the ... studied, classified and compared to each other, ... a glance. Automatized scanning of the hybridized ...
Biology Products: